In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Acurx Pharmaceuticals, with a price target of $31.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Keller has given his Buy rating due to a combination of factors that highlight the potential of Acurx Pharmaceuticals’ lead product, ibezapolstat. The company recently presented promising preclinical data at IDWeek ’25, demonstrating that ibezapolstat, a DNA pol IIIC inhibitor, exhibits microbiome-sparing properties. This selectivity in the gut is crucial as it helps preserve beneficial bacteria, which can enhance the drug’s efficacy in treating difficult bacterial infections and reduce the risk in late-stage studies.
Additionally, ibezapolstat has shown impressive clinical efficacy in a Phase 2a/b trial for treating C. difficile infection (CDI). The trial results indicated a high Clinical Cure rate of 96%, significantly surpassing the historical cure rates of traditional treatments like vancomycin. These outcomes, combined with the drug’s favorable safety profile, suggest a strong potential for success in future clinical trials, supporting Keller’s optimistic outlook and Buy rating for Acurx Pharmaceuticals.
According to TipRanks, Keller is a 4-star analyst with an average return of 15.1% and a 59.26% success rate. Keller covers the Healthcare sector, focusing on stocks such as FibroGen, Acurx Pharmaceuticals, and Gyre Therapeutics.